Drug Type Single-chain FV antibody fragment |
Synonyms DNX-514 |
Target |
Mechanism TNF inhibitors(Tumor necrosis factor inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization DNX Biopharmaceuticals, Inc.Startup |
Active Organization- |
Inactive Organization DNX Biopharmaceuticals, Inc.Startup |
Drug Highest PhaseDiscontinuedPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
AS | Preclinical | US | DNX Biopharmaceuticals, Inc.Startup | 31 Aug 2022 |
Arthritis, Psoriatic | Preclinical | US | DNX Biopharmaceuticals, Inc.Startup | 31 Aug 2022 |
Colitis, Ulcerative | Preclinical | US | DNX Biopharmaceuticals, Inc.Startup | 31 Aug 2022 |
Crohn Disease | Preclinical | US | DNX Biopharmaceuticals, Inc.Startup | 31 Aug 2022 |
Juvenile Idiopathic Arthritis | Preclinical | US | DNX Biopharmaceuticals, Inc.Startup | 31 Aug 2022 |
Plaque psoriasis | Preclinical | US | DNX Biopharmaceuticals, Inc.Startup | 31 Aug 2022 |
Rheumatoid Arthritis | Preclinical | US | DNX Biopharmaceuticals, Inc.Startup | 31 Aug 2022 |